United We Stand: Regulatory Framework For Biosimilars May Bring Indian And MNCs Closer
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD - Amid numerous fights over patents of leading drug brands, Indian and multinational drug companies may be seeing some sense in working cohesively to help the Indian government establish standard regulations and allow development and launch of future biosimilars and novel biotechnology-based drugs